Hongni Fan

Hongni Fan

Auto-generated profile, based on publicly available information

Hongni Fan

Johns Hopkins University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
KSKellie N. Smith
Kellie N. Smith
NLNicolas J Llosa
Nicolas J Llosa
TCTricia R. Cottrell
Tricia R. Cottrell
NSNicholas Siegel
Nicholas Siegel
HFHongni Fan
Hongni Fan
FHFranck Housseau
Franck Housseau
Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor mutational burden (TMB) also being explored with promising results, and mismatch-repair deficiency is approved for tumor site-agnostic disease. While tumors with high PD-L1 expression, high TMB, or mismatch repair deficiency respond well to checkpoint blockade, tumors with lower PD-L1 expression, lower mutational burdens, or mismatch repair proficiency respond much less frequently. Case presentation We studied two patients with unexpected responses to checkpoint blockade monotherapy: a patient with PD-L1-negative and low mutational burden NSCLC and one with mismatch repair proficient colorectal cancer (CRC), both of whom lack the biomarkers associated with response to checkpoint blockade, yet achieved durable clinical benefit. Both maintained T-cell responses in peripheral blood to oncogenic driver mutations – BRAF-N581I in the NSCLC and AKT1-E17K in the CRC – years after treatment initiation. Mutation-specific T cells were also found in the primary tumor and underwent dynamic perturbations in the periphery upon treatment. Conclusions These findings suggest that T cell responses to oncogenic driver mutations may be more prevalent than previously appreciated and could be harnessed in immunotherapeutic treatment, particularly for patients who lack the traditional biomarkers associated with response. Comprehensive studies are warranted to further delineate additional predictive biomarkers and populations of patients who may benefit from checkpoint blockade.

20 March 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
LCLiam Chung
Liam Chung
DMDavid Maestas
David Maestas
ALAndriana Lebid
Andriana Lebid
AMAshlie Mageau
Ashlie Mageau
GRGedge D. Rosson
Gedge D. Rosson
JEJennifer Elisseeff
Jennifer Elisseeff
Synthetic biomaterials and medical devices suffer to varying levels from fibrosis via the foreign body response (FBR). To explore mechanistic connections between the immune response and fibrosis from the FBR, we first analyzed fibrotic capsule surrounding human breast implants and found increased numbers of interleukin (IL)17-producing γδ + T cells and CD4 + T H 17 cells as well as senescent cells. Further analysis in a murine model demonstrated an early innate IL17 response to synthetic implants, mediated by innate lymphoid cells and γδ + T cells, was followed by a chronic adaptive antigen dependent CD4 + T H 17 cell response. Mice deficient in IL17 signaling established that IL17 was required for the fibrotic response to materials and the development of p16 INK4a senescent cells. Treatment with a senolytic agent reduced IL17 expression and fibrosis. Discovery of a feed-forward loop between the T H 17 and senescence response to synthetic materials introduces new targets for therapeutic intervention in the foreign body response.